Introduction {#s0001}
============

Metoclopramide is a dopamine antagonist used to prevent nausea and vomiting owing to its antiemetic properties and action as a prokinetic drug.[@cit0001] However, neurologic adverse events caused by metoclopramide, including extrapyramidal disorders, have been reported and are known to be the cause of drug-induced parkinsonism.[@cit0002]--[@cit0004]

In February 2009, the Food and Drug Administration (FDA) published a drug safety communication with a black box warning about the adverse drug event of metoclopramide including tardive dyskinesia.[@cit0005],[@cit0006] The European Medicine Agency (EMA) also recommended changes to the use of metoclopramide, including restrictions on the indication, the maximum administration period, and the maximum daily dose in 2013.[@cit0007] Based on the EMA recommendations and medical specialists' advice, the Korean Ministry of Food and Drug Safety (MFDS) published a safety letter regarding the use of metoclopramide in October 2013. The safety letter included recommendations with regard to the indications, prescription, and dosage of metoclopramide However, the effects of a safety letter from the MFDS during post-marketing surveillance are mixed. Previous studies have shown that a safety letter from the MFDS can change the drug utilization pattern,[@cit0008] whereas other studies have reported that safety letter from the MFDS had a limited impact on treatment use in clinical practice.[@cit0009] A safety letter from the MFDS is an important national policy option in Korea for pharmacovigilance and risk management.[@cit0009],[@cit0010] A reliable and valid evaluation of the effectiveness of a healthcare policy can be used as evidence to support good decision making in real-world clinical settings.[@cit0011] To effectively manage the serious drug adverse events of metoclopramide such as extrapyramidal disorder and to optimize the impact of the safety letter, it is necessary to evaluate the effectiveness of this policy. Therefore, the objective of this study was to assess the effect of the safety letter on changes in the prescription patterns of metoclopramide in Korea between January 2011 and December 2015.

Materials and Methods {#s0002}
=====================

Data Sources {#s0002-s2001}
------------

We analyzed the national claims data from the Health Insurance Review and Assessment Service (HIRA). HIRA is the government agency that evaluates the medical and pharmacy expenditure of health insurance covering the entire population of approximately 50 million (the Korean National Health Insurance accounts for approximately 97%, and Medical Aid covers approximately 3%) in Korea. The claims data from the HIRA contain comprehensive and unidentified information, such as diagnoses, procedures, treatments, surgeries, and prescriptions.[@cit0012] We extracted all claims containing a metoclopramide prescription between 2011 and 2015 from this data to analyze the utilization pattern. This study was exempted from approval by the Institutional Review Board of the Pusan National University Korean Medicine Hospital (PNUIRB/2016_27_HR), owing to the use of anonymized claims data in which participants were not identifiable.

Intervention and Variables {#s0002-s2002}
--------------------------

The MFDS issued the safety letter for metoclopramide in October 2013; this safety letter included the following: (1) With regard to indications; the recommendation that metoclopramide should not be prescribed as a single agent for gastrointestinal disorders and as an adjunct in surgical and radiological procedures and that metoclopramide should only be used as a second-line option for the prevention of postoperative nausea and vomiting and delayed chemotherapy-induced nausea and vomiting in children; (2) with regard to prescription; the recommendation that metoclopramide should only be prescribed for short-term use (up to 5 days); (3) with regard to dosage; the recommendation that the maximum dose of metoclopramide that should be prescribed in 24 hours should be 0.5 mg/kg for adults and children; and (4) with regard to age; the recommendation that metoclopramide is contra-indicated in children under 1 year of age.[@cit0013] Through these recommendations limiting the indication, prescription period, and dosage, the MFDS tried to minimize the risk of adverse drug events caused by metoclopramide. We hypothesized that the utilization pattern of metoclopramide, including the number of prescriptions, prescription period, and dosage, would be decreased after the publication of the safety letter compared with that before publication. To evaluate this, we estimated three types of outcomes to analyze the effect of the safety letter on the utilization patterns of metoclopramide. First, we estimated the number of prescriptions per month to assess the impact of the restriction of the indications in the safety letter on the utilization pattern. Next, we estimated the average administration period per prescription per month to evaluate the association between the recommendation on the maximum administration period in the safety letter and the change in the prescription patterns of metoclopramide. Finally, we measured the average dose per prescription per month to analyze the effect of the restriction of the daily maximum dose on utilization change.

Data Analysis {#s0002-s2003}
-------------

To assess the change in the utilization pattern, we conducted an interrupted time-series analysis (ITSA) using HIRA claims data that included metoclopramide usage between January 2011 and December 2015. ITSA is one of the most useful and simple quasi-experimental designs for the identification of the impact of healthcare policies or interventions when a randomized controlled trial is not possible or clinical trial data are not available. Many researchers have used ITSA methodologies to evaluate the effectiveness of healthcare policies.[@cit0008],[@cit0014]--[@cit0019] In recent years, several studies have suggested a scientific process and recommendations for ITSA including methodology and reporting. We performed an ITSA comparing the utilization pattern of metoclopramide before and after the publication of the safety letter with reference to these recommendations.[@cit0011],[@cit0020]--[@cit0024] In the ITSA, the regression line is segmented before and after the occurrence of the intervention or event to be analyzed. Each segmented regression line is represented by two parameters, level (or intercept) and slope (or trend). The impact of the event on the outcomes can be described in terms of a change in the level or slope. The segmented regression model for ITSA was as follows: $$\documentclass[12pt]{minimal}
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where Y~t~ was the outcome variable (ie, the number of prescriptions, the average administration period per prescription, and the average dose per prescription) over time t; TIME1 was the continuous time in months from 0 (for January 2011) to 60 (for December 2015); POLICY was a binary variable indicating the publication of the safety letter as the point intervention, where 1 indicated that it had been published and 0 indicated that it has not; TIME2 is the continuous time in months from 0 (for October 2013) to 26 (for December 2015), with a value of 0 before the publication of the safety letter. The error term ε~t~ refers to a random variable that cannot be explained by the model. In this model, the coefficient β~0~ indicated the baseline level of the outcomes per month when TIME1 was zero (for January 2011); β~1~ estimated the baseline trend before the publication of the safety letter; β~2~ estimated the outcome change immediately after the publication of the safety letter; and β~3~ represented the change in the trend after the safety letter was released, compared with β~1~. Thus, β~1~ + β~3~ shows the outcome (change in the trend) after the safety letter was issued.

For this segmented linear regression, it is important to control for autocorrelation and seasonality. Autocorrelation represents a serial correlation between adjacent outcome data.[@cit0021],[@cit0022] For example, the drug utilization pattern in time~k~ may be correlated with time~k+1~, through a first-order autocorrelation. If the time unit of ITSA is months and the order of autocorrelation is 12 or 24 months, it is an example of seasonality.[@cit0022] Autocorrelation may lead to biased results, including an underestimated standard error and overestimated significance.[@cit0022] To detect and correct autocorrelation among the observations, we performed an ITSA with the Durbin-Watson test.[@cit0021] Then, to correct for autocorrelation, we used the Yule-Walker method with the BACKSTEP option. This method can automatically test for correlations and sequentially removes insignificant autoregressive parameters until only significant autoregressive parameters remain at the 0.05 level.[@cit0021],[@cit0025]--[@cit0027]

The other issue to consider in ITSA is immediacy. Immediacy is described as the amount of delayed (or lagged) time until the effect of the intervention occurs.[@cit0020]--[@cit0022],[@cit0024],[@cit0028] For example, if a policy is implemented, the policy may take a certain period of time to have an effect on the clinical event.[@cit0020]--[@cit0022] Therefore, researchers should consider the appropriate lag time for the proper effect to appear in the segmented regression model. In this study, we hypothesized that there would be a time lag of approximately 4 months for the complete impact of the metoclopramide safety letter to be evident.[@cit0020]--[@cit0022],[@cit0024] To take this issue into consideration, we excluded the lag time period (between October 2013 and February 2014) from the analysis by referring to previous studies.[@cit0022] We performed all analyses using SAS version 9.4 (Copyright SAS Institute Inc., Cary, NC, USA).

Results {#s0003}
=======

We analyzed 40,730,545 prescriptions for metoclopramide between January 2011 and December 2015 from the HIRA claims data (29,857,752 cases before safety letter issuance and 10,872,793 cases after safety letter issuance). The results of the ITSA, including the trends in the utilization patterns per month during the study period, are shown in [Figure 1](#f0001){ref-type="fig"}. The number of prescriptions per month (718,182--1,183,194 before the publication of the safety letter and 328,215--566,043 after the publication of the safety letter) followed no significant trend (TIME1: 3435, p-value = 0.09), and there was no significant alteration in the trend after the publication of the safety letter (TIME2: −4705, p-value = 0.26). However, the number of prescriptions per month decreased immediately after the safety letter was released (POLICY: −531,543, p-value \<0.01). The trend in the average administration period per prescription per month (4.28--4.94 days before the publication of the safety letter and 2.55--3.78 days after the publication of the safety letter) did not show a significant change before the safety letter (TIME1: 0.01, p-value = 0.09). However, after the release of the safety letter, the estimate and trend were significantly decreased compared with that before the publication of the safety letter (POLICY: −1.32, p-value \<0.01; TIME2: −0.05, p-value \<0.01). The average dose per prescription per month (18.27--19.21 mg before the publication of the safety letter and 15.39--16.93 mg after the publication of safety letter) followed a decreasing trend before the safety letter (TIME1: −0.02, p-value \<0.01). The average dose per prescription per month decreased immediately after the publication of the safety letter (POLICY: −1.88, p-value \<0.01) and there was no significant change in the trend compared with that before the safety letter was released (TIME2: −0.01, p-value = 0.63) ([Table 1](#t0001){ref-type="table"}). The absolute values of the outcomes per month are presented in the [[supplementary data](http://www.dovepress.com/get_supplementary_file.php?f=263579.xlsx)]{.ul}.Table 1Parameters from the Interrupted Time-Series Analysis of Utilization PatternsUtilization PatternInterceptTIME1POLICYTIME2β~0~ Estimates\
(SE)p-valueβ~1~ Estimates\
(SE)p-valueβ~2~ Estimates\
(SE)p-valueβ~3~ Estimates\
(SE)p-valueNumber of prescriptions per month831,799\
(39,296)\< 0.013435\
(1988)0.09−531,543\
(60,898)\< 0.01−4705\
(4101)0.26Average administration period per prescription per month (days)4.58\
(0.08)\< 0.010.01\
(0.003)0.09−1.32\
(0.11)\< 0.01−0.05\
(0.01)\< 0.01Average dose per prescription per month (mg)19.03\
(0.13)\< 0.01−0.02\
(0.007)\< 0.01−1.88\
(0.19)\< 0.01−0.01\
(0.01)0.63[^1][^2] Figure 1Results of the interrupted time-series analysis with segmented regression method.

Discussion {#s0004}
==========

This study showed that the recommendations in the safety letter published by the MFDS, which restricted the indications, maximum dose to be administered, and maximum daily dose of metoclopramide, may be associated with a change in utilization patterns in Korea. The number of prescriptions per month, the average administration period per prescription per month, and the average dose per prescription per month decreased significantly after the publication of the safety letter. These decreases may have been attributable to the safety letter. Among the changes in the prescribing patterns, only the average administration period per prescription per month after the release of the safety letter decreased significantly compared with that before the publication of the safety letter. This may be related to the characteristics of extrapyramidal disorders as a side effect of metoclopramide. The occurrence of extrapyramidal disorders is closely related to the period of metoclopramide use.[@cit0029] Owing to the issuance of the safety letter by the MFDS, the prescription period of metoclopramide may have been gradually shortened as much as possible to minimize the occurrence of these adverse drug events.

The issuance of a safety letter by the MFDS is an important post-marketing drug safety management system used in Korea. If the discontinuation or restriction of drug use is required owing to the potential risk of severe adverse drug events, the MFDS will rapidly release a safety letter and perform various follow-up actions, such as the revocation or amendment of pharmaceutical approval.[@cit0030] The safety letter summarizes evidence from domestic and foreign drug safety and contains cautionary information on prescribing, dosing, dispensing, and administration. The Korean government and MFDS established a drug utilization review (DUR) system in 2008 to monitor adverse drug event in real time based on post-marketing pharmacovigilance systems such as a safety letter.[@cit0031] However, the DUR system provided very limited information, and the impact of the safety letter by the MFDS on clinical practice is uncertain and controversial.[@cit0009] A previous study, which analyzed the safety letters issued by the MFDS between 2001 and 2011, reported that the safety letters did not affect actual clinical practice owing to the inefficient system for risk communication.[@cit0009] Therefore, it is necessary to provide evidence to support the improvement of public health through safe medication use, by evaluating the impact of the safety letter. The results of our study showed that the MFDS safety letter for metoclopramide was associated with an immediate reduction in utilization patterns. The safety letter for metoclopramide issued in October 2013 contained an amendment for metoclopramide approval, as well as recommendations for changes to the use of metoclopramide, with restrictions on the indication, maximum administration period, and maximum daily dose.[@cit0013] A recent study evaluating a safety letter for pioglitazone also showed similar results.[@cit0032] This study showed that the release of a safety letter including a warning regarding the risk of bladder cancer led to a moderate decrease in pioglitazone users. According to another study that assessed the effect of the FDA's post-marketing drug safety surveillance on the use of metoclopramide, a black box warning about the adverse events of metoclopramide has decreased drug usage.[@cit0006] In addition, several studies on the drug safety management system have reported the significant impact on drug utilization patterns.[@cit0014],[@cit0033]--[@cit0035] Based on these results, the safety letter issued by the MFDS can be regarded as a factor that influences a change in prescribing patterns. In particular, if there are strong actions, such as the revocation or amendment of pharmaceutical approval, the relationship between safety letters and changes in prescribing patterns may become apparent.

To the best of our knowledge, this is the first study to assess the effect of the publication of a safety letter by the MFDS on changes in the prescribing patterns of metoclopramide in Korea. In addition, we conducted an ITSA using nationally representative claims data that covers the entire population. Previous studies analyzing the effect of policy on metoclopramide in the US and Europe have used limited data sources.[@cit0006],[@cit0019] These studies showed the change in the utilization pattern of metoclopramide by examining the electronic medical records of an university hospital over 24 or 30 months, comparing that before and after the policy implementation.[@cit0006],[@cit0019] Compared with these studies, our study analyzed national insurance claims data covering the whole population over 60 months, thereby ensuring the representativeness of our research results. We did not investigate the impact of the metoclopramide safety letter on the use of alternative drugs such as domperidone. Further investigations may be needed to identify the effect of the safety letter of metoclopramide on the drugs that have replaced metoclopramide.

Despite these strengths, we should interpret the results with caution owing to the limitations of the interrupted time-series study design. If there were other factors associated with the use of metoclopramide in addition to the events or policies that we were interested in, these may have affected the results.[@cit0022] However, to the best of our knowledge, no other policies or events could have directly affected metoclopramide use other than the safety letter issued in October 2013.

Conclusion {#s0005}
==========

This study suggests that the safety letter containing recommendations on medication usage and the amendment of pharmaceutical approval issued by the MFDS was associated with changes in the prescription patterns of metoclopramide. The results of our study may be used as evidence for the evaluation of the effectiveness of the safety letter as a post-marketing surveillance policy. Further studies to explore the characteristics of safety letters and optimize their impact may contribute to the development of safety letters as a more effective drug safety management system.
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[^1]: **Notes:** Intercept is a value of utilization pattern in January 2011. TIME1 is a continuous variable that takes the value of "1" for January 2011 and increases by one per month. TIME2 starts at 0, takes the value of "1" for October 2013, and increases by one per month. POLICY is a dummy variable representing the publication of the safety letter in October 2013.

[^2]: **Abbreviation:** SE, standard deviation.
